Untch M, et al. - Researchers assessed long-term outcomes among patients with primary breast cancer (BC) who showed significant improvement in pathologic complete remission rate with weekly nanoparticle albumin-bound (NAB)–paclitaxel vs weekly solvent-based (sb) paclitaxel followed by epirubicin plus cyclophosphamide as neoadjuvant treatment in the GeparSepto trial. In a random manner, the participants were allocated (1:1 ratio) to 12 times weekly NAB-paclitaxel 150 mg/m² (following study amendment, 125 mg/m²) or weekly sb-paclitaxel 80 mg/m² followed in both arms by four times epirubicin 90 mg/m² plus cyclophosphamide 600 mg/m²every 3 weeks. Participants were followed-up for a median of 49.6 months. NAB-paclitaxel treatment was associated with a significantly higher pathologic complete response rate, which led to a significantly better invasive disease-free survival in patients with early BC, vs sb-paclitaxel. NAB-paclitaxel 125 mg/m² vs NAB-paclitaxel 150 mg/m² led to a much quicker improvement of peripheral sensory neuropathy.